The FDA also cleared a 23andMe genetic health risk report for a syndrome associated with a higher risk of developing hereditary colorectal cancer.
The firm's Life Sciences segment grew 10 percent year over year during the quarter while its Diagnostics segment was up 4 percent.
The company expects EPS to be between $4.02 and $4.12. On a non-GAAP basis, EPS is expected to be in the range of $4.75 and $4.85.
Sysmex accuses 13 Beckman Coulter instruments of infringing 11 claims in the patent, which covers a system analyzer and a computer program.
A court in San Diego has stated that part of the suit between Quidel and Beckman is void as a matter of law.
Within diagnostics, Beckman Coulter saw core revenue growth in the low-single digits, while Cepheid was up in the double digits for the quarter.
The firm said that its system is expected to deliver up to 50 AST tests per day and match the daily production of the highest-throughput systems in the market.
The test uses the same blood draw of a routine health exam and was designed to be unaffected biotin, a vitamin supplement that may skew some lab test results.
The Canadian regulator gave Medical Device License approval to Beckman Coulter's DxH 900 Hematology Analyzer and its Early Sepsis Indicator.
With the partnership, Beckman will this month launch the iQ Urinalysis Workcell in the US. The workcell consists of an automated urine analyzer from each company.